- Method for industrially producing aceclofenac
-
The invention relates to a method for industrially producing aceclofenac. The method comprises the following steps: mixing organic acid, a water removal agent and Lewis acid, fully stirring, and adding aceclofenac tert-butyl ester for acidolysis reaction. The method is mild in reaction condition, high in reaction rate, free of high temperature and high energy consumption, easy and convenient to operate, environmentally friendly, economical and free of participation or generation of major pollutants, most solvents can be recycled, emission of waste solvents is reduced, and therefore the cost isreduced, and the environment is protected.
- -
-
Paragraph 0029-0030
(2020/11/12)
-
- METHODS FOR PREPARING ACECLOFENAC AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
The present invention relates to a method for preparing aceclofenac and a pharmaceutical preparation comprising aceclofenac prepared by using the same, and provides a method for preparing aceclofenac that can obtained in a more uniform particle size compared to the prior art. The pharmaceutical preparation containing aceclofenac prepared according to the method of the present invention has a small particle size, uniformity and excellent dispersibility, and can minimize a content of excipients, and thus can be applied to various pharmaceutical composition formulations without limitation.COPYRIGHT KIPO 2021
- -
-
Paragraph 0105; 0107; 0109
(2020/10/20)
-
- Method for producing aceclofenac tert-butyl ester
-
The invention relates to a method for producing aceclofenac tert-butyl ester. The method includes: allowing diclofenac sodium, tert-butyl bromoacetate, catalyst iodide and tetrabutylammonium hydrogensulfate to have reaction in water, slowly cooling, cryst
- -
-
Paragraph 0021; 0022
(2019/10/17)
-
- Preparation method of aceclofenac
-
The invention discloses a microwave-assisted preparation method of aceclofenac. The method is as follows: under the microwave condition, a compound 2 and a compound 3 are reacted to form a compound 4under the catalysis of KI; and under the microwave condition, a reaction of the compound 4 is carried out in a mixed solvent of formic acid and acetone. According to the method, the acidolysis of aceclofenac tert-butyl ester is carried out in the mixture of formic acid and acetone under the microwave condition, the acidolysis method has high selectivity, the fracture of the ethoxyl group in aceclofenac tert-butyl ester is reduced to the lowest limit, the conversion rate of the acidolysis reaction is high, the diclofenac content in the product is extremely small, the product is easy to refine,and the purity is high.
- -
-
Paragraph 0034-0035
(2019/08/30)
-
- Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
-
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
- -
-
Page/Page column 53
(2010/11/30)
-